437 related articles for article (PubMed ID: 21140231)
21. Lymph node metastasis of squamous cell carcinoma from an unknown primary in the upper and middle neck: Impact of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography.
Deron PB; Bonte KM; Vermeersch HF; Van de Wiele C
Cancer Biother Radiopharm; 2011 Jun; 26(3):331-4. PubMed ID: 21711095
[TBL] [Abstract][Full Text] [Related]
22. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
Wu ZJ; Zhang YX; Wei H; Jia Q
Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
[TBL] [Abstract][Full Text] [Related]
23. Predictive factors for ipsilateral or contralateral central lymph node metastasis in unilateral papillary thyroid carcinoma.
Koo BS; Choi EC; Yoon YH; Kim DH; Kim EH; Lim YC
Ann Surg; 2009 May; 249(5):840-4. PubMed ID: 19387316
[TBL] [Abstract][Full Text] [Related]
24. Clinical implications of bilateral lateral cervical lymph node metastasis in papillary thyroid cancer: a risk factor for lung metastasis.
Lee YS; Lim YS; Lee JC; Wang SG; Kim IJ; Son SM; Lee BJ
Ann Surg Oncol; 2011 Nov; 18(12):3486-92. PubMed ID: 21553141
[TBL] [Abstract][Full Text] [Related]
25. Implication of lymph node metastasis detected on 18F-FDG PET/CT for surgical planning in patients with peripheral intrahepatic cholangiocarcinoma.
Park TG; Yu YD; Park BJ; Cheon GJ; Oh SY; Kim DS; Choe JG
Clin Nucl Med; 2014 Jan; 39(1):1-7. PubMed ID: 24335565
[TBL] [Abstract][Full Text] [Related]
26. Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer.
Ohara M; Shigematsu H; Tsutani Y; Emi A; Masumoto N; Ozaki S; Kadoya T; Okada M
Breast; 2013 Oct; 22(5):958-63. PubMed ID: 23756383
[TBL] [Abstract][Full Text] [Related]
27. Clinical value of (18)F-FDG PET/CT in postoperative monitoring for patients with colorectal carcinoma.
Han A; Xue J; Zhu D; Zheng J; Yue J; Yu J
Cancer Epidemiol; 2011 Oct; 35(5):497-500. PubMed ID: 21296635
[TBL] [Abstract][Full Text] [Related]
28. Non-FDG-avid primary papillary thyroid carcinoma may not differ from FDG-avid papillary thyroid carcinoma.
Kim MH; Ko SH; Bae JS; Lee SH; Jung CK; Lim DJ; Baek KH; Kim SH; Lee JM; Kang MI; Cha BY
Thyroid; 2013 Nov; 23(11):1452-60. PubMed ID: 23688271
[TBL] [Abstract][Full Text] [Related]
29. Usefulness of 18-F FDG PET/CT in the pre-treatment evaluation of thymic epithelial neoplasms.
Terzi A; Bertolaccini L; Rizzardi G; Luzzi L; Bianchi A; Campione A; Comino A; Biggi A
Lung Cancer; 2011 Nov; 74(2):239-43. PubMed ID: 21439670
[TBL] [Abstract][Full Text] [Related]
30. Comparison of F-18-FDG PET/CT findings between pancreatic solid pseudopapillary tumor and pancreatic ductal adenocarcinoma.
Kim YI; Kim SK; Paeng JC; Lee HY
Eur J Radiol; 2014 Jan; 83(1):231-5. PubMed ID: 24290142
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of ¹⁸F-α-methyl tyrosine PET/CT for the detection of bone marrow invasion in patients with oral squamous cell carcinoma: comparison with ¹⁸F-FDG PET/CT and MRI.
Kim M; Higuchi T; Arisaka Y; Achmad A; Tokue A; Tominaga H; Miyashita G; Miyazaki H; Negishi A; Yokoo S; Tsushima Y
Ann Nucl Med; 2013 Jun; 27(5):423-30. PubMed ID: 23436243
[TBL] [Abstract][Full Text] [Related]
32. [Positron emission tomography-computed tomography with (18)F-fluorodeoxyglucose in patients with recurrent differentiated thyroid carcinoma and negative radioiodine scan. Diagnostic performance and relation with tyroglobulin levels].
Mariscal Labrador E; García Burillo A; Castell-Conesa J; Obiols Alfonso G; Kisiel González N; Barios Profitós M; Aguadé-Bruix S; Mesa Manteca J
Rev Esp Med Nucl Imagen Mol; 2013; 32(3):146-51. PubMed ID: 22726673
[TBL] [Abstract][Full Text] [Related]
33. Clinical value of visually identifiable 18F-fluorodeoxyglucose uptake in primary papillary thyroid microcarcinoma.
Hwang SO; Lee SW; Kang JK; Choi HH; Kim WW; Park HY; Jung JH
Otolaryngol Head Neck Surg; 2014 Sep; 151(3):415-20. PubMed ID: 24903453
[TBL] [Abstract][Full Text] [Related]
34. Thyroid incidentalomas on FDG PET/CT in patients with non-thyroid cancer - a large retrospective monocentric study.
Kim H; Kim SJ; Kim IJ; Kim K
Onkologie; 2013; 36(5):260-4. PubMed ID: 23689220
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic value and therapeutic impact of (18)F-FDG-PET/CT in differentiated thyroid cancer. Results of a German multicentre study.
Riemann B; Uhrhan K; Dietlein M; Schmidt D; Kuwert T; Dorn R; Sciuk J; Kodalle T; Schober O
Nuklearmedizin; 2013; 52(1):1-6. PubMed ID: 23192295
[TBL] [Abstract][Full Text] [Related]
36. Interest of (18)F-FDG PET-CT scanning for staging and management of merkel cell carcinoma: a retrospective study of 15 patients.
Maury G; Dereure O; Du-Thanh A; Mariano-Goulart D; Guillot B
J Eur Acad Dermatol Venereol; 2011 Dec; 25(12):1420-7. PubMed ID: 21366705
[TBL] [Abstract][Full Text] [Related]
37. Is (18)F-FDG-PET/CT prognostic factor for survival in patients with small cell lung cancer? Single center experience.
Inal A; Kucukoner M; Kaplan MA; Urakci Z; Nas N; Guven M; Dostbil Z; Altindag S; Isikdogan A
Rev Port Pneumol; 2013; 19(6):260-5. PubMed ID: 23993406
[TBL] [Abstract][Full Text] [Related]
38. Outcome of clinical stage III melanoma patients with FDG-PET and whole-body CT added to the diagnostic workup.
Niebling MG; Bastiaannet E; Hoekstra OS; Bonenkamp JJ; Koelemij R; Hoekstra HJ
Ann Surg Oncol; 2013 Sep; 20(9):3098-105. PubMed ID: 23612885
[TBL] [Abstract][Full Text] [Related]
39. Role of FDG PET-CT in asymptomatic epithelial ovarian cancer with rising serum CA-125: a pilot study.
Ghosh J; Thulkar S; Kumar R; Malhotra A; Kumar A; Kumar L
Natl Med J India; 2013; 26(6):327-31. PubMed ID: 25073988
[TBL] [Abstract][Full Text] [Related]
40. Incidental thyroid carcinoma by FDG-PET/CT: a study of clinicopathological characteristics.
Law TT; Lang BH
Ann Surg Oncol; 2011 Feb; 18(2):472-8. PubMed ID: 20740320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
